Want to track IDYA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
IDYA earnings report is expected in 35 days (31 Mar 2026)
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
Monday, IDEAYA Biosciences Inc IDYA released clinical data for the IDE397 Phase 2 monotherapy expansion dose in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients (NSCLC).
Benzinga | 1 year ago
Why Ideaya Biosciences Just Made Its Most Bullish Move Since March
Ideaya Biosciences presented promising results Monday for a drug that tackles hard-to-treat cancers. The biotech stock surged.
Investors | 1 year ago
